Navigation Links
Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
Date:7/22/2009

ouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088

About FORADIL((R))

FORADIL((R)) AEROLIZER((R)) is for the maintenance treatment of asthma in those 5 years and older when taken on a long-term, twice-daily basis. FORADIL AEROLIZER should only be used as additional therapy for patients not adequately controlled on other asthma controller medications.

FORADIL AEROLIZER is not indicated for patients whose asthma can be managed by occasional use of fast-acting rescue inhalers. FORADIL AEROLIZER is also for the acute prevention of exercise-induced bronchospasm (EIB) in those 5 years of age and older when administered on an occasional, as-needed basis at least 15 minutes before exercise.

FORADIL AEROLIZER is for the long-term, twice-daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema.

Important Safety Information for FORADIL AEROLIZER

FORADIL belongs to a class of medications known as long-acting beta2-adrenergic agonists or LABAs. In patients with asthma, LABAs may increase the chance of asthma related death. Therefore, FORADIL should only be used as additional therapy for patients not adequately controlled on other asthma controller medications.

In asthma clinical trials, the most common adverse events reported with FORADIL AEROLIZER were viral infection, bronchitis, and chest infection.

In COPD clinical trials, the most common adverse events reported with FORADIL AEROLIZER were upper respiratory infection, back pain, and sore throat.

FORADIL capsules should only be inhaled orally us
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
2. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
3. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
4. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
5. Schering-Plough Reports Top-Line Results of the IDEAL Study
6. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
7. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
8. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
9. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
10. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
11. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 27, 2015  Pomerantz LLP is investigating claims on ... the "Company") (NASDAQ: VTAE ).  Such investors ... at rswilloughby@pomlaw.com or 888-476-6529, ext. 237. ... its officers and/or directors have violated Sections 10(b) and ... On February 27, 2015, the Company announced ...
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers ... board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ... per share. Concerned SLXP investors are encouraged to contact ... The investigation focuses upon the shareholder value ... Salix shareholders would receive only $158.00 per share in ...
(Date:2/27/2015)... Report Details   ... R&D progress, and predicted revenues ,Where is the market ... commercial prospects for this market and related technologies? Visiongain,s ... trends to 2025, discussing data, opportunities and prospects. ... regenerative medicine : cell-based therapies that aim to restore ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2Translational Regenerative Medicine: Market Prospects 2015-2025 2Translational Regenerative Medicine: Market Prospects 2015-2025 3Translational Regenerative Medicine: Market Prospects 2015-2025 4Translational Regenerative Medicine: Market Prospects 2015-2025 5Translational Regenerative Medicine: Market Prospects 2015-2025 6Translational Regenerative Medicine: Market Prospects 2015-2025 7Translational Regenerative Medicine: Market Prospects 2015-2025 8
... Varian Medical Systems, Inc. (NYSE: VAR ), ... cancer with radiotherapy, announced today it has received Shonin ... Welfare (MHLW) to market the TrueBeam™ system for image-guided ... of lung, breast, prostate, head and neck, and other ...
... June 15, 2011 Reportlinker.com announces that a ... catalogue: US Cardiac Assist Devices ... http://www.reportlinker.com/p0555154/US-Cardiac-Assist-Devices-–-Market-Trend-Till-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Cardiovascular_Devices Short ... vital market data on the cardiac assist devices ...
Cached Medicine Technology:TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval 2TrueBeam™ System for Non-Invasive Image-Guided Cancer Treatment Receives Shonin Approval 3Reportlinker Adds US Cardiac Assist Devices -- Market Trend Till 2016 2Reportlinker Adds US Cardiac Assist Devices -- Market Trend Till 2016 3
(Date:3/1/2015)... CrossFit Attollo is a CrossFit gym located in Vancouver ... to new members. Now through the end of March ... will receive their fourth month half off. , ... The three month contract is only $264, dropping the price ... comes in at only $55. The special saves new members ...
(Date:2/28/2015)... February 28, 2015 In recent years Medical ... of practicing physicians as a way for them to expand ... regarding Cannabis as medicine. Since the FDA still lists Cannabis ... resources available to licensed physicians that can help guide ... Dr. Deborah Malka in Santa Cruz, CA is a ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 In ... Duncan Fletcher of Game Change Athlete ... Shannon Leinert about the benefits of athlete development and ... some of the unique challenges that athletes face and ... and future success. , Fletcher became involved in athlete ...
(Date:2/28/2015)... 2015 With their commitment to achieving ... an additional exercise to their already robust library of ... most commonly known as, is often performed on a ... executed in a relatively safe manner and can be ... The full description of “Rope Pulls” is located in ...
(Date:2/28/2015)... Portland, Oregon (PRWEB) February 28, 2015 ... Portland, Oregon, is offering a new special. Throughout ... denture relines. , This service ... from sleep problems and pain. Patients may notice certain ... and need relining. These symptoms include: , 1.    Pain, ...
Breaking Medicine News(10 mins):Health News:CrossFit Gym in Vancouver WA Offers Spring Special 2Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Classic Denture Center in Portland Oregon is Offering March Discount 2
... have found a new family of therapeutic agents that ... growth of breast cancer cells. The results of the ... The Endocrine Society,s 90th Annual Meeting in San Francisco. ... therapeutic called TPBM and related compounds are likely to ...
... have discovered a new family of agents that inhibit ... described today at a meeting of the Endocrine Society, ... to combat estrogen-dependent breast cancers. , "This cell-based study ... to be effective in tumors that remain dependent on ...
... treatments, researchers say , , MONDAY, June 16 (HealthDay News) ... that might one day be added to the armamentarium ... "This is a potential new approach to treating hormonally ... officer of the American Cancer Society. "If it proves ...
... 16 The National Center for Healthcare,Leadership (NCHL) ... MD, chief,executive officer of Denver Health, as the ... her significant and lasting contributions,to healthcare. Under her ... system that achieves organizational,excellence while treating at-risk populations, ...
... S.C., June 16 The planned,Presbyterian College school of ... the dean of the school of pharmacy and assistant,provost ... Charleston,W. Va. has accepted the college,s offer to become ... developing the first school of pharmacy in,Upstate South Carolina., ...
... of RU-486,s companion drug misoprostol is safe, but vaginal use ... a drug given with RU-486 to terminate a pregnancy may ... in women taking the drugs since 2000, a study by ... is FDA-approved to be taken by mouth along with RU-486 ...
Cached Medicine News:Health News:Future hope for patients with breast cancers resistant to tamoxifen 2Health News:Team discovers new inhibitors of estrogen-dependent breast cancer cells 2Health News:New Molecule Discovery Shows Promise Against Tamoxifen-Resistant Breast Cancers 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 2Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 3Health News:Denver Health's Dr. Patricia Gabow Receives NCHL's 2008 National Healthcare Leadership Award 4Health News:Presbyterian College Announces First Dean of New Pharmacy School 2Health News:Presbyterian College Announces First Dean of New Pharmacy School 3Health News:Abortion drug's off-label use may have led to deaths 2Health News:Abortion drug's off-label use may have led to deaths 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: